News | February 26, 2015

Massachusetts Breast Surgeon Presenting on BioZorb Surgical Marker at International Conference

Three-dimensional device helps track tumor site after lumpectomy for more precise radiation treatment

BioZorb, Focal Therapeutics, breast cancer, Schonholz, conference

Steven Schonholz, M.D., FACS, breast surgeon and director of the Center for Comprehensive Breast Health at Noble Hospital, stands in one of the exam rooms.

February 26, 2015 — A Noble Hospital breast surgeon's work with a new device that improves treatment of breast cancers will be featured later this month at a prestigious international medical conference.

Steven Schonholz, M.D., FACS, will present a scientific poster at the 32nd annual Miami Breast Cancer Conference, in Miami Beach, Fla., Feb. 26 to March 1. Schonholz will focus on BioZorb, a novel three-dimensional bioabsorbable surgical marker which helps physicians track the tumor site after lumpectomy surgery to remove cancer and deliver more precise radiation treatment.

Schonholz was the first physician in Massachusetts to use BioZorb as part of his medical practice. He is director of the Center for Comprehensive Breast Health at Noble Hospital.

BioZorb contains several tiny titanium clips positioned in a 3-D pattern inside a bioabsorbable coil. The body eventually resorbs the coil, leaving the titanium clips for long-term visualization of the surgery site.

"This unique device does a better job of helping us protect healthy tissue around the surgical site during radiation therapy," said Schonholz. "It can also provide our patients with a more satisfying cosmetic result after treatment."

The work by Schonholz that is being recognized at the Miami conference includes an infographic explaining how BioZorb is used in the treatment of breast cancer. Among advantages of the marker that are outlined in the infographic are these:

  • It is readily placed by the surgeon and can be easily visualized.
  • It helps target the radiation therapy to a smaller target area which results in less radiation to normal tissues.
  • It provides a stable 3-D identification of where the tumor was prior to removal, to help with treatment and longer-term follow-up.


Preliminary experience suggests the BioZorb infographic effectively informs patients and clinicians about an advanced tissue marking method and improves communication between the breast surgeon and radiation oncologist, according to the poster.

For more information:

Related Content

RSNA Study Shows Real-Time Indicator Improves Mammographic Compression
News | Mammography | December 12, 2018
Sigmascreening recently announced that more than 100,000 women have had mammography exams with the Sensitive Sigma...
Massachusetts Superior Court Grants Hologic Preliminary Injunction in Trade Secrets Lawsuits
News | Mammography | December 12, 2018
December 12, 2018 — A Massachusetts Superior Court granted a preliminary injunction in lawsuits by Hologic against Ch
Videos | Mammography | December 10, 2018
Stamatia Destounis, M.D., FACR, associate professor, University of Rochester School of Medicine, and attending radiol
FDA Clears iCAD's ProFound AI for Digital Breast Tomosynthesis
Technology | Mammography | December 07, 2018
iCAD Inc. announced clearance by the U.S. Food and Drug Administration (FDA) for their latest, deep-learning, cancer...
Fujifilm Collaborates With Lunit on AI Pilot Project
News | Artificial Intelligence | December 05, 2018
Fujifilm Medical Systems USA Inc. announced a joint collaboration with Korean-based medical artificial intelligence (AI...
ScreenPoint Medical and Volpara Partner to Bring AI to Breast Imaging Clinics
News | Computer-Aided Detection Software | December 04, 2018
ScreenPoint Medical has signed a memorandum of understanding (MOU) with Volpara Health Technologies. Volpara will...
GE Healthcare Introduces Invenia ABUS 2.0
Technology | Ultrasound Women's Health | December 03, 2018
GE Healthcare recently launched the Invenia automated breast ultrasound (ABUS) 2.0 system in the United States. This...
Snoring Poses Greater Cardiac Risk to Women
News | Women's Health | November 29, 2018
Obstructive sleep apnea (OSA) and snoring may lead to earlier impairment of cardiac function in women than in men,...
ScreenPoint Medical Receives FDA Clearance for Transpara Mammography AI Solution
Technology | Computer-Aided Detection Software | November 28, 2018
November 28, 2018 — ScreenPoint Medical announced it has received 510(k) clearance from the U.S.
Women Benefit From Mammography Screening Beyond Age 75
News | Mammography | November 26, 2018
Women age 75 years and older should continue to get screening mammograms because of the comparatively high incidence of...